Mental health, addiction treatments with psychedelics: could the UK lead the way?

Strangely, Brexit and then the Covid-19 pandemic have combined to create ideal conditions for the UK to potentially become a leader in psychedelics research.

From Brexit came conditions for a new “fast-track” medicinal approval regulatory pathway. This combined with increased emphasis on life sciences as well as streamlined research and risk-assessment changes brought about by Covid-19 to create an ideal scenario for psychedelics start-ups to take off.  However, before these new enterprises can fully get going, further conditions must still be met, such as acceptance by UK medical professionals of treatments using psychedelics.


Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Erik Galavis
+34 654 320 547
Email Erik

Pablo Sharrock
+34 722 642 678
Email Pablo